Visitar site em português
NOV 5 . Escola de Hotelaria e Turismo de LISBOA

UNDERSTANDING BRCA

Where we are. Where to go.

NOV 5 Congress

The Kick-Start

The First steps in research on hereditary cancer have been taken, but there is still a way to go. Our aim for this Congress is very clear: to set up the basis for creating a Portuguese / European consortium of research on hereditary cancer.

The world’s leading specialists

Some of the world’s leading specialists on this field will join us, to share their knowledge, their experiences and most of all their vision on how a network to fight hereditary cancer effectively should look like.

Let’s work together

To be successful we need to join forces: doctors, laboratories, researchers, authors, institutions and organizations. Because together we are stronger.
Meet our speakers or Contact us.

EVITA - Associação de Apoio a Portadores de Alterações nos Genes Relacionados com Cancro Hereditário.

This Congress is organized by Evita – Associação de Apoio a Portadores de Alterações nos Genes relacionados com Cancro Hereditário.

Evita aims to raise awareness in society on the risk of Hereditary Cancer. Its goal is to improve the quality of life for patients and to be the active voice towards authorities, medical and scientific communities, the media, similar associations and the general public.

Come and meet us

Speakers

Meet our speakers, some of the world’s leading specialists in hereditary cancer research.

Professor Steven Narod

Professor Steven Narod

Women’s College Research Institute, Toronto, Canada

Professor Jacek Gronwald

Professor Jacek Gronwald

Pomeranian Medical University, Poland

Rita Schmutzler

Professor Rita Schmutzler

University Hospital of Cologne, Germany

Doctor Angela George

Doctor Angela George

ICR, Royal Marsden Hospital, London

Professor Manuel Teixeira

Professor Manuel Teixeira

Francisco Gentil Portuguese Oncology Institute, Porto, Portugal (IPOPFG)

Doctor Fátima Vaz

Doctor Fátima Vaz

Francisco Gentil Portuguese Oncology Institute, Lisbon, Portugal (IPOLFG)

Professor Leonor David

Professor Leonor David

Portuguese Cancer Research Association, Portugal (ASPIC)

Doctor Joana Paredes

Doctor Joana Paredes

Institute of Molecular Pathology and Immunology, University of Porto, Portugal

Doctor Ana Berta Sousa

Doctor Ana Berta Sousa

Santa Maria Hospital, Lisbon, Portugal

Professor Luís Costa

Professor Luís Costa

Institute of Molecular Medicine (IMM), University of Lisbon
Portuguese Cancer Research Association, Portugal (ASPIC)

Doctor Nuno Miranda

Doctor Nuno Miranda

Directorate General for Health, Lisbon, Portugal

Tamara Hussong Milagre

Tamara Milagre

Evita Association

Learn more about the Congress Programme or Contact us.

PROGRAMME

14:00 – 14:10 Welcome speech by Nuno Miranda (DGS) and Tamara Milagre (Evita)
SESSION 1 Moderators: Leonor David (ASPIC) and Nuno Miranda.
14:10 – 14:40 Steven Narod
Women’s College Research Institute, Toronto, Canada
Recent advances in the treatment of hereditary breast cancer.
14:40 – 15:00 Jacek Gronwald
Pomeranian Medical University, Szczecin, Poland
Selected aspects of prophylactic measures in BRCA1/2 mutation carriers.
15:00 – 15:20 Rita Schmutzler
University Hospital of Cologne, Germany
The German Consortium.
15:20 – 15:40 20′ questions session.
15:40 – 15:50 10′ coffee break.
SESSION 2 Moderators: Joana Paredes (Ipatimup) and Berta Sousa (Sta. Maria).
15:50– 16:20 Angela George
ICR, Royal Marsden Hospital, London
The Mainstreaming Cancer Genetics (MCG) programme.
16:20 – 16:35 Manuel Teixeira
Francisco Gentil Portuguese Oncology Institute, Porto, Portugal (IPOPFG)
Inherited predisposition to prostate cancer.
16:35 – 16:50 Fátima Vaz
Francisco Gentil Portuguese Oncology Institute, Lisbon, Portugal (IPOLFG)
BRAC1/2 mutations and cancer susceptibility in Portugal.
16:50 – 17:10 20′ questions session.
SESSION 3 Moderators: Nuno Miranda, Luis Costa (IMM, ASPIC) and Steven Narod.
17:10 – 18:00 Round Table
Networking in Portugal: Patient referral & Scientific collaboration & International cooperation.
18:00 – 18:10 Closing speech by Nuno Miranda and Tamara Milagre

Registration

Come and listen to the world’s leading specialists on hereditary cancer.

  • Free access to the Congress.
  • Please complete and submit the registration form.
  • Coffee break included.
  • Let us know if you wish to join us at the Networking Buffet.
  • Registrations are limited to the premises’ capacity.

Together we are stronger
Contact us.

Networking Buffet

Networking BuffetSource: hoteldaestrela.com

Join us for dinner with our speakers, a unique opportunity to meet and talk with the specialists.

The Networking Buffet Dinner will take place after the congress at the Hotel da Estrela, close to the congress’ premises, at a charge of 30€ per person.

Do not miss this opportunity.

Additional information


If you have any questions, please contact us at brcanetwork@evitacancro.org or use our form.

Contact us


Natasha Hall – International Artist

As part of a much bigger project, Natasha is making a documentary style video about her personal experience. Natasha will be in Lisbon presenting her work in process.

Watch in only 20 seconds her preparation and recovery from a preventative double mastectomy with reconstruction, after diagnosis of the BRCA2 genetic mutation.

More about Natasha Hall

Venue LISBON

Where exactly is it?

Staying in Lisbon?

Source: hoteldaestrela.com

For your convenience you may benefit from special booking conditions at Hotel da Estrela, where the Networking Buffet will take place.

Learn more about Hotel da Estrela

Meet the city

Meet the city

Source: visitlisboa.com

Lisbon is considered one of the most beautiful cities in the world and worth a visit.
Enjoy and meet the city.

Discover Lisbon

Register for the European BRCA Congress 2015

Find us

EVITA - Associação de Apoio a Portadores de Alterações nos Genes Relacionados com Cancro Hereditário.EVITA -Associação de Apoio
a Portadores de Alterações nos Genes
Relacionados com Cancro Hereditário.

Register and help us to achieve our goals.





  • Free entry to the congress.
  • To participate, please complete and submit the registration form (Contact us).
  • Coffee break is included.
  • Let us know if you wish to join us at the Networking Buffet.
  • You will receive a confirmation email with additional information and payment details, should you decide to join us for dinner.
  • Your registration will be confirmed within 5 days.
  • Registrations are limited to room capacity.

Evita wants to save lives.

Contact us.

Sponsors and Supporters

Astra Zeneca


myriad

Supporters

Virgin Active - 1 dia de livre circulação Escola de Hotelaria e Turismo de Lisboa Hotel da Estrela Language Solutions Câmara Municipal de Lisboa Delta Cafés El Corte Inglés

Tamara Milagre
Tamara Hussong Milagre
Evita Association

Tamara has been a nurse for 25 years, but she also has a personal concern with the hereditary breast and ovarian cancer, as she comes from a family of high risk for the disease and carries the BRCA1 gene mutation.
When she became aware of her genetic risk in 2008, she decided to join a team of scientists, doctors, nurses, psychologists and patients to create Evita, an association that supports families affected by hereditary cancer. As the President of the Association, she has organized patient meetings and she has been an active voice among the medical and scientific communities, the media, similar associations and the general public. She frequently attends scientific meetings related to hereditary cancer. She cooperates with international associations, such as BRCA Netzwerk (Germany), BRCA Sisterhood, BRCA Group Administrators and FORCE (USA), BRCA Umbrella (United Kingdom), BRCA France (France) and Braca (Israel), where she gets to talk with thousands of people affected.

Tamara Milagre will take over the opening and the closing of the Congress.

CLOSE

Nuno Miranda
Doctor Nuno Miranda
Directorate General for Health, Lisbon, Portugal

Nuno Miranda graduated in Medicine from Lisbon University in 1986. He specialized in Clinical Hematology and started working at the Lisbon IPO in 1989. From 1994 to 1996 he was a fellow of the European Cancer Centre, at Netherlands Kanker Instituut in Amsterdam. He worked at the IPO Medular Transplants Unit since 1996 and holds the title of Graduate Assistant for Clinical Hematology since 2000. He worked as Clinical Director at the IPO from 2009 to 2012. He is a member of CEIC since 2009 and Director of the National Cancer Diseases Programme since 2012. He is also member of the European Blood and Marrow Transplantation and the American Society of Hematology.

Doctor Nuno Miranda will take over the opening and closing of the Congress. He will be also one of the moderators of Session 3 (panel session)that will take place from 5:10 to 6:00 pm.

CLOSE

Luís Costa
Professor Luís Costa
Institute of Molecular Medicine (IMM), University of Lisbon
Portuguese Cancer Research Association, Portugal (ASPIC)


Dr Luís Costa is Professor of Medicine at the Lisbon Medical School – University of Lisbon, Portugal and he is the head of the Clinical Translational Oncology Research Unit at IMM since 2007. Dr. Luis Costa serves also as director of Oncology Department at Hospital de Santa Maria in Lisbon since 2005, and was appointed in 2015 as director of the Clinical Research Center at Lisbon Medical Academic Center. At the School of Medicine he is the Coordinator Professor of “Oncobiologia” a new teaching unit that aims to teach the understanding of clinical oncology through molecular medicine, and he acts as member of the Editorial board of Harvard Medical School Portugal Program. Dr. Luis Costa is the IMM Portuguese representative of the Global Cancer Genomics Consortium.
Dr. Luis Costa acts also as an expert for grant reviews at the European Research Council, the Cancer Research UK, CAIBER (Spanish Clinical Research Network), and the French National Cancer Institute. Professor Costa’s clinical research, publications and scientific presentations have primarily focused on bone metastases, related to breast cancer, prostate cancer and other solid tumors. He has published various peer-reviewed papers discussing these topics.

Professor Luís Costa will be one of the moderators of Session 3 (panel session) that will take place from 5:10 to 6:00 pm.

CLOSE

Ana Berta Sousa
Doctor Ana Berta Sousa
Santa Maria Hospital, Lisbon, Portugal

1995 – Medical Degree from the Faculdade de Ciências Médicas da Universidade Nova de Lisboa (Lisbon, Portugal).
1996 – Concluded one-year of pre-doctoral training in the Gulbenkian Institute of Science (Oeiras, Portugal).
2000 – Ph.D. in Genetics from the Mathematisch-Naturwissenschaftliche Fakultät der Universität zu Köln (Cologne, Germany).
2003 – Qualified for independent clinical practice after two years of supervised training in clinical medicine at Hospital São Francisco Xavier (Lisbon, Portugal).
2003 – Enrolled as Assistent Professor for Immunology at Faculdade de Medicina de Lisboa (Lisbon, Portugal).
2008 – Concluded the specialisation in Medical Genetics after a five-year training programme at Hospital Santa Maria (Lisboa, Portugal).
2008 – Enrolled as Consultant in Clinical Genetics at Hospital Santa Maria (Lisboa, Portugal).
2010 – Enrolled as clinical geneticist at Hospital da Luz (Lisboa, Portugal).
2013 – Appointed head of the Genetics Unit of Hospital Santa Maria (Lisboa, Portugal).

Doctor Ana Berta Sousa will be one of the moderators of Session 2 that will take place from 3:50 to 5:10 pm.

CLOSE

Joana Paredes
Doctor Joana Paredes
Institute of Molecular Pathology and Immunology, University of Porto, Portugal

Joana Paredes (JParedes) is Principal Investigator at the Cancer Genetics group at IPATIMUP and Affiliated Professor at the Department of Pathology and Oncology at the Faculty of Medicine of the University of Porto.
JParedes’s research focus is to identify important molecular markers for breast cancer management and treatment, with a special focus on poor prognosis basal-like breast cancer. In clinical terms, JParedes found that de novo expression of the adhesion molecule P-cadherin is overexpressed in near 30% of breast carcinomas, being a poor prognostic factor for patients. Further, she identified molecular mechanisms underlying P-cadherin aberrant expression in breast cancer, such as epigenetic events, as well as transcription factors. JParedes still identified P-cadherin-associated molecular partners and signalling and how its activation promotes cancer cell invasion, which involves MMPs secretion, ECM remodeling, as well as alterations in cancer metabolim. Importantly, she verified that P-cadherin confers stem cell properties to breast cancer cells, turning them resistant to standard cancer therapies.
JParedes has 54 publications in international peer-review journals, with a total number of 1302 citations, with an h-index of 21. She got funding as PI from different sources, including National Science Foundation (FCT) and Gulbenkian Foundation, Novartis and Sanofi-Aventis International, and Associação Laço.

Doctor Joana Paredes will be one of the moderators of Session 2 that will take place from 3:50 to 5:10 pm.

CLOSE

Leonor David
Professor Leonor David
Portuguese Cancer Research Association, Portugal (ASPIC)

Leonor David was born in Porto, Portugal, in 1955. Leonor David is a Pathologist and Full Professor of Pathology at the Medical Faculty of Porto, Porto, Portugal. She received a degree in medicine and earned her Ph.D. degree from the Medical Faculty of Porto, Portugal, in 1979 and 1993, respectively. She did part of her Ph.D. and postdoctoral research at the Radium Hospital in Oslo, Norway and at the University of Copenhagen, Denmark. Her main interest is focused on mucins and mucin glycosylation in gastric carcinogenesis. She is also particularly interested in the regulation of events leading to intestinal metaplasia. Leonor David participated in the organizing committee of several international meetings on cancer and mucin/mucin glycosylation, published over 100 papers in journals with peer-review, wrote 6 book chapters, is Member of the Council of the European Association for Cancer Research. Leonor David is president of ASPIC (Portuguese Association for Cancer Research).

Professor Leonor David Pereira will be one of the moderators of Session 1 that will take place from 2:10 to 3:40 pm.

CLOSE

Fátima Vaz
Doctor Fátima Vaz
Francisco Gentil Portuguese Oncology Institute, Lisbon, Portugal (IPOLFG)

Medical Oncologist ( Consultant) and Hereditary Breast/Ovarian multidisciplinar group, (Coordinator) at the Lisbon Centre of the Portuguese Institute of Oncology.
Member of the Executive Committee of the National Ethics Committee for Clinical Research.
Main interests are hereditary breast, ovarian and prostate cancer: genetic and modifier factors.

Doctor Fátima Vaz will speak from 4:35 to 4:50 pm about “BRAC1/2 mutations and cancer susceptibility in Portugal.”

CLOSE

Manuel Teixeira
Professor Manuel Teixeira
Francisco Gentil Portuguese Oncology Institute, Porto, Portugal (IPOPFG)

Manuel R. Teixeira, MD, PhD, is the Director of the Genetics Department at the Portuguese Oncology Institute of Porto and a guest Full Professor of Pathology and Genetics at the Biomedical Sciences Institute of the University of Porto. He obtained his PhD (Dr Med) degree in Medicine (Medical Genetics) at the University of Oslo, where we worked for several years at the Institute for Cancer Research, The Norwegian Radium Hospital (now part of Oslo University Hospital). He has published more than 200 articles on cancer genetics in international scientific journals, which can be found in the following links: Genetics Service | IPO-PORTO e Publications List

Professor Manuel Teixeira will speak from 4:20 to 4:35 pm about “Inherited predisposition to prostate cancer.”

CLOSE

Angela George
Doctor Angela George
Royal Marsden Hospital, London

I completed my specialty training in Medical Oncology in New Zealand, and began as a consultant Medical Oncologist, with a particular interest in ovarian and breast cancer. I subsequently moved to The Royal Marsden Hospital, where I worked in the Gynae unit, then began research into the germline genetics of ovarian cancer. During this time, I led the implementation of the Mainstreaming Cancer Genetics programme within the Gynae and Breast units. After completion of my thesis, I was appointed as a Consultant in Oncogenetics at The Royal Marsden. I am continuing my research interests into ovarian cancer genetics, and continue to lead implementation of the Mainstreaming Cancer Genetics programme.

Doctor Angela George will speak from 3:50 to 4:20 pm about “The Mainstreaming Cancer Genetics (MCG) program.”

CLOSE

Rita Schmutzler
Professor Rita Schmutzler
University Hospital of Cologne, Germany

Professor Rita Schmutzler is a gynecologist and coordinates the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) that comprises 15 university-based centres throughout the country. Her focus lies on translational medicine which is why she put major efforts in establishing best practice in preventive health care for women at risk. She also strongly supported the formation of the German self-help group “BRCA-Netzwerk” of whom she is a founder member. Meanwhile the “BRCA-Netzwerk” is member of all committees of the GC-HBOC thereby ensuring its participation in all strategic decisions on how to further improve health care for women at risk.

  • Director, Centre Familial Breast and Ovarian Cancer, University Hospital of Cologne
  • Professor, Medical Faculty of Cologne University.
  • Member of the guideline committees for breast and ovarian cancer of the German Cancer Society.
  • Member of the commission for genetic diagnostic at the Robert-Koch Institute in Berlin.
  • Member of the expert panel of the National Cancer Plan of the Federal Ministry of Health.

Professor Rita Schmutzler will speak from 3:00 to 3:20 pm about “The German Consortium.”

CLOSE

Jacek Gronwald
Professor Jacek Gronwald
Pomeranian Medical University, Poland

Jacek Gronwald MD, PhD Born on 07.08.1965 in Koszalin, Poland. Professor. Dean of the Faculty of Medicine, Biotechnology and Laboratory Medicine of Pomeranian Medical University. Regional Consultant in clinical Genetics. Specialist in gynaecology-obstetrics and clinical genetics. Graduated in medicine in 1991 in Pomeranian Medical University. Phd in field of oncological genetics – 1997 in Pomeranian Medical University. Habilitation in field of oncological genetics – 2008 in Pomeranian Medical University. Scientific focus: cancer genetics especially risk estimation and prevention of hereditary breast and ovarian cancer. Author and coauthor of over 200 papers mainly in field of cancer genetics with IF over 1050, cited about 6000 times, and h-index 43.

Professor Jacek Gronwald will speak from 2:40 to 3:00 pm about “Selected aspects of prophylactic measures in BRCA1/2 mutation carriers.”

CLOSE

Steven
Professor Steven Narod
Women’s College Research Institute, Toronto
Dr. Narod is a world-leader in the field of breast and ovarian cancer genetics. Over the course of his career, he has profoundly shaped current knowledge of how to assess breast and ovarian cancer risk and reduce its mortality amongst carriers of BRCA1 and BRCA2 mutations. He studies various aspects of cancer prevention and screening, proving that prophylactic surgeries and medications can prevent hereditary breast/ovarian cancers.

Professor Steven Narod will speak from 2:10 to 2:40 pm about “Recent advances in the treatment of hereditary breast cancer.”

CLOSE
Contact us

For any questions, please contact us. We will reply to you within 24 hours.




This message will be sent to
brcanetwork[at]evitacancro.org.
For any questions, please contact us.

Please leave this field empty.

CLOSE